---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-114764"
form_type: "8-K/A"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2026-03-19T23:59:59+00:00"
generated_at: "2026-05-15T09:36:26.364078+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Catalyst Pharma patent trial delayed to May 18, 2026 in NJ district court

## Summary
- District Court of NJ delayed bench trial between Catalyst and Hetero USA from Mar 23 to May 18, 2026.
- Trial concerns validity of Orange Book-listed patents for FIRDAPSE expiring in 2032, 2034, and 2037.
- The trial is a bench trial (judge only) and will be held in the District of New Jersey.

## SEC filing metadata
- accession: 0001193125-26-114764
- form_type: 8-K/A
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2026-03-19T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312526114764/0001193125-26-114764-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312526114764/d25173d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-114764
- JSON: https://secwatch.observer/filing/0001193125-26-114764.json
- Plain text: https://secwatch.observer/filing/0001193125-26-114764.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.